Jiachen Li

Jiachen Li

Auto-generated profile, based on publicly available information

Jiachen Li

Department of Rheumatology and Immunology, Peking University People's Hospital; Beijing Key Laboratory of Non-invasive Diagnosis and Immunotherapy of Rheumatic Diseases (Peking University People's Hospital), Beijing, 100044, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2025 in Rheumatology
Verified
Journal Article
Open access
JLJiachen Li
Jiachen Li
WXWeiyi Xia
Weiyi Xia
HJHuijuan Ji
Huijuan Ji
XGXiaoxin Gong
Xiaoxin Gong
QDQi Dong
Qi Dong
TLTian Liu
Tian Liu
Objective: This study aimed to assess the efficacy and safety of baricitinib in Takayasu arteritis (TAK) refractory to TNF-α inhibitors. Methods: We conducted a multicentre, single-arm trial between February 2021 and August 2023. Patients with TAK unresponsive to at least 6 months of TNF-α inhibitors were treated with baricitinib 4 mg daily for up to 48 weeks, while continuing of immunosuppressants and glucocorticoids. Clinical features, inflammatory parameters, imaging changes and treatment data were collected during follow-up. The primary end point was the overall response (ORR) (complete response [CR] plus partial response [PR]) at 24 weeks. Results: A total of 10 patients (nine female and one male) patients were enrolled, with median age of 29 years (26.0, 35.3) and a median disease duration of 56.5 months (31.8, 88.5). The ORR at 24 weeks was 80%, with six patients achieving CR and two achieving PR. Disease progression was noted in the remaining two patients. Disease activity, ESR and CRP at 24 weeks were significantly decreased compared with those at baseline. The median glucocorticoid dosage decreased from 20.0 mg/day (15.0, 26.3) at baseline (P < 0.001) to 6.3 mg/day (4.4, 10.6) at 24 weeks. No relapse was observed in the eight patients who achieved a response. The adverse effects (AEs) included upper respiratory tract infection (n = 2) and diarrhoea (n = 1), with no serious AEs reported. Conclusion: Baricitinib is effective in patients with TAK resistant to conventional treatments and anti-TNF-α therapy and demonstrates a notable steroid-sparing effect. Trial registration: ClinicalTrials.gov; NCT06662721.

3 March 2026 in Arthritis Research & Therapy
Verified
Journal Article
Open access
JLJiachen Li
Jiachen Li
WXWeiyi Xia
Weiyi Xia
HJHuijuan Ji
Huijuan Ji
XGXiaoxin Gong
Xiaoxin Gong
QDQi Dong
Qi Dong
TLTian Liu
Tian Liu
This study aimed to evaluate the efficacy and safety of upadacitinib in patients with refractory Behcet’s syndrome (BS). A multicentre, single-arm trial was conducted from February 2023 to August 2025. Eligible patients had BS refractory to at least two immunosuppressive agents or one targeted therapy for a minimum of 6 months. Participants discontinued previous targeted therapies and received upadacitinib 15 mg/day for up to 48 weeks, in addition to their ongoing glucocorticoid and immunosuppressant regimens. Clinical features, inflammatory markers, imaging findings, and treatment data were collected throughout follow-up. The primary endpoint was the overall response rate (ORR; complete response [CR] plus partial response [PR]) at 24 weeks. Twenty-seven patients (16 male; median age 36 years) were enrolled, with a median baseline BDCAF score of 4 (range: 2–7). Affected systems included the mucocutaneous, articular, gastrointestinal, cardiovascular, and ocular systems. The ORR at 24 weeks was 85.2% (23/27), comprising 16 CRs and 7 PRs. Significant reductions were observed in median BDCAF scores, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and glucocorticoid dosage by week 24. Among the 23 patients who achieved remission at week 24, median CRP and ESR levels at 48 weeks were significantly lower than those at 24 weeks. For clinical responses across different systems, CR was achieved in 3 (100.0%) with cardiovascular involvement, 5 (83.3%) with ocular symptoms, 10 (76.9%) with gastrointestinal involvement, 16 (59.3%) patients with mucocutaneous symptoms, and 1 (16.7%) with articular involvement at 24 weeks. Three patients experienced relapse during the follow-up. No serious adverse events were reported. Upadacitinib represents a potential therapeutic option for patients with refractory BS. The online version contains supplementary material available at 10.1186/s13075-026-03778-x.

29 June 2026 in Arthritis Research & Therapy
Verified
Journal Article
Open access
JLJiachen Li
Jiachen Li
SJShanzhao Jin
Shanzhao Jin
FSFeng Sun
Feng Sun
MSMiao Shao
Miao Shao
XZXia Zhang
Xia Zhang
TLTian Liu
Tian Liu
This study aimed to use machine learning to explore Behçet's syndrome (BS) heterogeneity by integrating immunocyte subpopulations and clinical characteristics. We prospectively enrolled BS patients and recorded their demographic and clinical characteristics. Various peripheral immune cells were analysed using flow cytometry. Unsupervised machine learning was used to perform cluster analysis based on the clinical manifestations and immune cell subsets. Patients were followed up for one year to evaluate treatment response and remission rates. RNA sequencing was performed in patients with clustered BS and healthy controls. Unsupervised machine learning categorized 201 BS patients into four clusters with distinct clinical and immunological features. Cluster 1 showed isolated mucocutaneous lesions, low inflammation, and high remission, with transcriptomic enrichment in IFN-γ, IL-6, and JAK-STAT pathways. Cluster 2 featured arthritis, elevated inflammatory levels, and responded well to TNF-α inhibitors, with transcriptomic enrichment in TNF and B-cell activation pathways. Cluster 3 had cardiovascular involvement, reduced CLA+ Tregs, and also responded to TNF-α inhibitors, with transcriptomic enrichment in coagulation, platelet activation, and MAPK pathways. Cluster 4 demonstrated neurological involvement, elevated CD161⁺ Tregs, low remission, and a better response to mycophenolate mofetil, with transcriptomic enrichment in T-cell activation and NF-κB pathways. Unsupervised clustering of BS patients revealed four distinct subtypes with significant clinical and immunological heterogeneity, which may provide a foundation for mechanistic studies and personalized treatment.

15 February 2026 in The Journal of Rheumatology
Verified
Journal Article
Closed access
JLJiachen Li
Jiachen Li
YXYangyang Xie
Yangyang Xie
JGJianping Guo
Jianping Guo
XLXue Li
Xue Li
LRLimin Ren
Limin Ren

18 March 2026 in ACR Open Rheumatology
Verified
Journal Article
Open access
JLJiachen Li
Jiachen Li
WXWeiyi Xia
Weiyi Xia
FSFeng Sun
Feng Sun
YLYingni Li
Yingni Li
YHYuke Hou
Yuke Hou
TLTian Liu
Tian Liu
Objective: Behçet syndrome (BS) is a systemic autoimmune vasculitis characterized by immune dysregulation involving multiple immune cell subsets. CD161 + Treg cells exhibit proinflammatory properties and impair immune regulation during inflammation. This study aimed to investigate the alterations in CD161 + Treg cells in BS and their clinical relevance, particularly in disease pathogenesis and neurologic involvement. Methods: This prospective multicenter study included 182 patients diagnosed with BS at the three hospitals between 2018 and 2024, 166 patients with systemic lupus erythematosus (SLE) and 149 patients with rheumatoid arthritis (RA) and 114 patients with healthy controls (HCs). Demographic and clinical data were recorded. CD4 + CD25 high CD127 low CD161 + T cells (CD161 + Treg cells) in peripheral blood were analyzed via flow cytometry. Statistical analysis included the Wilcoxon rank‐sum test, Fisher's exact test, and logistic regression, with P < 0.05 considered significant. Results: Patients with BS had a significantly higher proportion among total Treg cells and CD4 + T cells, as well as higher absolute number of CD161 + Treg cells compared to HCs. CD161 + Treg cell levels negatively correlated with Foxp3 + Treg cells and positively correlated with Teff cells. Patients with BS had higher absolute number of CD161 + Treg cells than that in patients with SLE and in patients with RA. Moreover, patients with BS with higher erythrocyte sedimentation rate or C‐reactive protein or with neurologic involvement exhibited higher CD161 + Treg cells, which were identified as a risk factor for neurologic involvement. Among 41 patients with BS observed after treatment, CD161 + Treg cells significantly decreased, correlating with reduced disease activity. Conclusion: Patients with BS exhibit an increased CD161 + Treg cells in peripheral blood, which may contribute to immune dysregulation and neurologic involvement. The reduction of CD161 + Treg cells following treatment suggests their potential role as a biomarker for disease activity in BS.